Isoflurane

Quick links to important sections

Isoflurane

Treatment option: Anesthesia

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Isoflurane

Quick Facts

Property Description
Active ingredient Isoflurane
Form Inhalation Solution (volatile liquid)
Pharmacological class General Anesthetic, Volatile Agent
Common use Inducing and maintaining surgical unconsciousness
Origin Synthetic (Halogenated Ether)

What is Isoflurane?

Isoflurane is a potent, synthetic medicine classified as a General Anesthetic. It is a prescription-only medicine whose fundamental role is to temporarily induce and maintain a state of reversible loss of consciousness for medical procedures. This medicine falls into the specific category of volatile anesthetic agents, meaning it is administered by inhalation to rapidly affect the central nervous system (CNS). Clinical experience across surgical fields has consistently recognized Isoflurane's efficacy in creating the controlled, unconscious state required for surgery, ensuring the patient experiences neither pain nor memory of the procedure.

What Type of Medicine is Isoflurane?

Isoflurane is chemically identified as a halogenated ether, a compound synthesized for anesthetic purposes. The inclusion of halogen atoms in this chemical structure is a key differentiating factor, providing benefits related to its stability and reduced metabolism in the body. The medicine's active core is the substance Isoflurane (the International Nonproprietary Name, or INN), making it a single active ingredient product. The World Health Organization lists Isoflurane as an essential medicine due to its critical role in facilitating safe and effective surgical interventions globally.

Composition and Form: The Inhalation Solution

Isoflurane is supplied as an inhalation solution, which is a pure volatile liquid that must be precisely vaporized before administration. This liquid preparation is 100% Isoflurane with no other base or vehicle required, enabling direct and precise delivery via the inhalation (pulmonary) route. As a volatile anesthetic, Isoflurane is administered using dedicated vaporizer equipment in a controlled setting. The use of this volatile liquid form is essential because it allows trained medical personnel to rapidly adjust the concentration of the vapor being breathed in by the patient, which is vital for maintaining safety and the correct depth of anesthesia throughout the procedure.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Isoflurane?

Possible Side Effects and Safety Information

Isoflurane's safety profile is documented by regulatory authorities, classifying adverse reactions by frequency and affected body system. The anesthetic's primary safety characteristics are defined by dose-dependent effects on the cardiovascular and respiratory systems, leading to predictable hypotension and respiratory depression as the depth of anesthesia is increased.

Adverse Reactions and Frequencies

Official labeling recognizes several reactions categorized by frequency. Common reactions reported, especially in the postoperative period, include nausea, vomiting, and shivering. Many other adverse reactions, such as anaphylactic reactions, cardiac arrest, QTc prolongation, and severe hepatic necrosis, are documented based on post-marketing spontaneous reports and are generally categorized as Not Known frequency.


Serious Adverse Reactions and Safety Constraints

Regulatory documents emphasize specific, serious adverse reactions. The most notable is the risk of Malignant Hyperthermia (MH), a potentially fatal hypermetabolic state in susceptible individuals. The label also documents cases of Perioperative Hyperkalemia (elevated serum potassium levels) resulting in cardiac arrhythmias and death, primarily reported in pediatric patients with latent neuromuscular disease. Other serious events include life-threatening cardiac arrhythmias like torsade de pointes and severe postoperative hepatic necrosis.


Population-Specific Safety Notes

The official labeling outlines specific safety considerations for vulnerable groups. For pediatric patients under three years and pregnant women in the third trimester, the FDA label includes a warning regarding prolonged or repeated exposure and potential effects on brain development. Furthermore, Isoflurane's uterine relaxant effect must be considered during obstetric procedures due to the associated risk of increased uterine bleeding (haemorrhage).

Overdose and Emergency Response

Overdose Manifestations and Required Actions

An overdose of Isoflurane results from an excessively high inspired concentration, leading to an excessive depth of anesthesia. The principal documented manifestations of overexposure include profound hypotension (severe drop in blood pressure) and marked respiratory depression (significantly decreased breathing), which compromise the cardiovascular and respiratory systems.

When to seek immediate medical help

Urgent medical attention is required immediately upon recognition of the signs of overdosage. The mandated first action is the immediate discontinuation of Isoflurane administration. Management is strictly symptomatic and supportive, which includes:

  • Establishing and maintaining a patent airway.
  • Initiating assisted or controlled ventilation with 100% oxygen.
  • Providing supportive measures to restore circulation.

Specific Overdose Risks and Management

A key risk noted in regulatory documents is the potential to trigger Malignant Hyperthermia (MH) in susceptible individuals. If this hypermetabolic state is triggered, it requires specific, immediate treatment, including the administration of dantrolene sodium. Furthermore, continuous monitoring of cardiovascular and respiratory status is necessary, as no specific chemical antidote is known for reversing the primary anesthetic effects of Isoflurane.

Therapeutic Uses of Isoflurane

What Isoflurane treats: main uses and benefits

Isoflurane is an inhalation general anesthetic that is commonly used in clinical settings that involve acute or unstable symptom patterns, such as surgical procedures. It belongs to the therapeutic domain of general anesthetics, and may be part of symptomatic management in situations where patients experience heightened physiological activity.

Its main uses are considered relevant for the induction and maintenance of general anesthesia. This means it is applied in scenarios where additional management of discomfort is required, assisting with conditions associated with acute or disruptive episodes.

In these contexts, it provides supportive relief that helps ease the overall symptom burden. As a general anesthetic, it is applied in addressing symptom clusters that may become intense or disruptive, specifically awareness, physical discomfort, and muscular activity during a medical intervention.

“This agent supports maintaining functional stability, which contributes to improved comfort for the patient during procedures.”

Isoflurane is relevant for easing the symptoms that create noticeable physiological strain, which is commonly used when short-term symptomatic assistance is needed.


Quick Fact: Relief for Physical Discomfort

Eligibility and Restrictions for Use

Who can and cannot use Isoflurane?

Isoflurane is approved for use in adult patients for both the induction and maintenance of general anesthesia, and for the maintenance of anesthesia in pediatric patients. However, official regulatory documents strictly define patient eligibility based on genetic history and pre-existing medical conditions.


Populations for whom use is Contraindicated

Isoflurane must not be administered to patients with:

  • Known or Suspected Genetic Susceptibility to Malignant Hyperthermia (MH).
  • A history of confirmed Hepatitis or severe Hepatic Dysfunction following prior exposure to a halogenated anesthetic agent.
  • Known sensitivity to Isoflurane or related halogenated agents.

Age and Condition Restrictions

  • Pediatric Induction: Use is not recommended for the induction of anesthesia in infants and children due to the risk of respiratory reactions.
  • Comorbidities: Special care is required for patients with Increased Intracranial Pressure (ICP), Coronary Artery Disease, or pre-existing neuromuscular diseases (e.g., Duchenne Muscular Dystrophy). Safety has not been fully established in those with severe renal impairment.
  • Pregnancy Status: Use during pregnancy is recommended only if clearly needed, due to the lack of adequate studies, and caution is noted regarding a relaxant effect on the uterus.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Medicinal products with documented interactions include Non-depolarizing muscle relaxants, Opioids, other respiratory depressants, and Nitrous Oxide. Isoflurane markedly potentiates the effects of non-depolarizing muscle relaxants and augments the respiratory depressant effects of opioids and other central nervous system depressants. Co-administration of Nitrous Oxide is documented to diminish the inspiratory concentration of Isoflurane required for general anesthesia.

Interaction-Related Restrictions

A critical procedural constraint involves a chemical reaction with the anesthetic equipment: Isoflurane can react with desiccated Carbon Dioxide absorbents (such as Barium Hydroxide Lime or Soda Lime) to produce Carbon Monoxide, leading to elevated carboxyhemoglobin levels in some patients.

Population and Substance Interaction Notes

Patients with a history of chronic alcohol ingestion may develop cross-tolerance, resulting in a higher required concentration of Isoflurane. In the pediatric population, the concomitant use of Succinylcholine is associated with an increased risk of perioperative hyperkalemia. The agent is strictly contraindicated in individuals with known or suspected susceptibility to Malignant Hyperthermia and those with sensitivity to halogenated anesthetics.

Connection to the overall interaction profile

The product's interaction profile is primarily defined by significant pharmacodynamic potentiation with other anesthetic and sedative agents, requiring careful management of co-administered drugs. Furthermore, a specific chemical reaction with CO2 absorbent materials introduces an important constraint related to the anesthetic delivery system itself.

Mechanism of Action

Isoflurane, a halogenated ether, acts by modulating several ion channels and receptors within the central nervous system ( CNS) and other body systems. Its effects are complex and multifactorial, altering neuronal membrane potential and excitability.

Modulation of Key CNS Inhibitory Pathways

Isoflurane exerts a major effect by acting as a positive allosteric modulator of the inhibitory GABA A receptor. This action enhances the effect of the body's primary inhibitory neurotransmitter, GABA, which increases chloride ion influx into neurons, leading to hyperpolarization and decreased neuronal excitability. It also potentiates the activity of glycine receptors, another key inhibitory pathway, resulting in decreased neuronal firing rates.


Inhibition of Excitatory Neurotransmission

Is it also engages mechanisms that suppress neuronal excitation, primarily by inhibiting the activity of NMDA-type glutamate receptors. Since glutamate is the main excitatory neurotransmitter, blocking its receptor activity modifies the early molecular steps in excitatory signaling, which suppresses subsequent action potential generation.


Ion Channel and Membrane Effects

Isoflurane also influences the function of various ion channels beyond neurotransmitter-gated ones, notably by modulating certain two-pore domain potassium K^+ ( K 2P) channels. The activation of these channels, such as TREK-1, contributes to neuronal membrane hyperpolarization and reduced neuronal activity. Additionally, the drug may affect intracellular calcium regulation and modify protein targets like ATP synthase, which facilitates cellular hyperpolarization.

Dosage and Administration Information

Instruction Map: How to use Isoflurane — official administration guidelines

Field Instruction
Route of administration Inhalation (Pulmonary Route)
Dosing schedule (as written in regulatory sources) For adults, Induction is typically achieved using inspired concentrations that range from 1.5% to 3.0%. Maintenance of surgical levels may be sustained with concentrations between 1.0% and 2.5% when used with nitrous oxide, or higher when administered with oxygen alone.
Timing in relation to meals (if applicable) Not applicable, as this agent is administered via the inhalation route during a controlled procedure.
Preparation requirements (if applicable) The volatile liquid formulation must be placed into a calibrated vaporizer specifically designed for Isoflurane to accurately control the inspired concentration.
Age-group administration rules The concentration needed for use varies with age: Older Adults typically require lower concentrations, while infants and young children may require higher concentrations for both induction and maintenance.
Missed-dose rules Not applicable, as usage is continuous for the defined procedure duration and not a daily scheduled regimen.
Special procedural conditions Administration must take place in an adequately equipped clinical environment and only by, or under the supervision of, personnel trained in general anesthesia.

Instruction classifications (high-level)

  • Administration method type (oral / IV / topical / inhaled / etc.): Inhaled (Volatile Agent)
  • Frequency pattern (daily / weekly / as-needed, etc.): Continuous (for the duration of the procedure)
  • Regulatory basis: Based on the official prescribing information published by government health authorities.
  • Use-context constraints (as defined in official documents): Requires specialized equipment and expert clinical supervision.

Resulting procedural structure

Official step sequence:

  • Initiate administration by delivering the Isoflurane vapor concentration, typically starting low and gradually increasing to achieve the desired induction state.
  • Titrate the concentration continuously throughout the procedure, adjusting the inspired level based on the patient's real-time response to maintain the required depth of the anesthetic state.
  • Discontinue administration when the surgical intervention is concluded, allowing for a rapid recovery phase.

Connection to the overall use protocol (3 sentences):

The official use protocol defines Isoflurane as a short-term, continuous-use agent requiring a highly controlled clinical environment. This framework mandates the use of calibrated equipment and expert personnel to ensure the inspired concentration is precisely managed and continuously adjusted (titrated). The regulatory instructions specify dose concentration ranges for induction and maintenance, emphasizing that requirements vary significantly based on patient age.

Recent Clinical Evidence

Isoflurane: Recent Clinical Evidence

Isoflurane is a widely used volatile inhalation anesthetic. While it has been in clinical use for decades, ongoing research continues to refine its role in various surgical and critical care settings. Clinical evidence focuses primarily on its effectiveness in maintaining surgical anesthesia, its hemodynamic effects, and its potential impact on organ systems.


Efficacy in Anesthesia Maintenance

Clinical trials consistently demonstrate the efficacy of isoflurane for the maintenance of general anesthesia across diverse patient populations and surgical procedures. The depth of anesthesia is dose-dependent and can be reliably controlled using measured concentrations. Studies highlight its rapid onset and offset, which contributes to quicker recovery times from anesthesia compared to some older agents.


Key Hemodynamic and Organ System Effects

Research has thoroughly investigated the cardiovascular effects of isoflurane. It typically causes a dose-dependent decrease in systemic vascular resistance, which can lead to a reduction in mean arterial pressure. Heart rate is generally well-maintained or slightly increased. Isoflurane's effect on cerebral blood flow (CBF) is an area of study, with findings indicating it can increase CBF, which must be managed in certain neurosurgical contexts.

In terms of renal and hepatic function, clinical evidence suggests that isoflurane is generally associated with minimal toxicity due to its low metabolism rate, meaning only a small fraction of the drug is processed by the liver.


Specialized Applications

Isoflurane remains an important option in settings where its specific pharmacological profile is beneficial. For instance, its ability to induce bronchodilation makes it a relevant agent for patients with reactive airway disease, as documented in several observational and comparative studies.

Frequently Asked Questions (FAQ)

Common questions about Isoflurane (FAQ)


Q: Is it normal to feel nauseous or vomit after being given Isoflurane?

According to official product information, yes, it is a common experience following general anesthesia with Isoflurane. Nausea and vomiting are listed among the most frequently reported adverse reactions that occur during the recovery period. Management of these symptoms is typically handled by the anesthesia or post-operative care team.


Q: What does MAC mean when people talk about Isoflurane?

MAC stands for Minimum Alveolar Concentration. This is a measure used by anesthesia specialists to gauge the potency of Isoflurane. It represents the concentration of the vapor required to prevent physical movement in half of patients when they are exposed to a surgical stimulus.


Q: Can Isoflurane cause a bad headache after the procedure?

Regulatory information indicates that headache is a documented adverse effect that has been reported after receiving Isoflurane. This symptom is typically reported in the post-operative period.


Q: How long after surgery with Isoflurane should I wait before driving?

Official guidelines indicate that patients should be advised to avoid engaging in hazardous tasks, such as driving an automobile, for at least 24 hours following general anesthesia. This precaution is necessary due to potential temporary effects on mental clarity and physical coordination.


Q: What kind of monitoring is done while a patient is receiving Isoflurane?

Monitoring is standardized during general anesthesia. This typically includes assessment of key bodily functions such as oxygen saturation (oxygenation), end-tidal CO2 levels (ventilation), heart activity (ECG), blood pressure (circulation), and body temperature.


Q: Does taking blood thinners interact with the administration of Isoflurane?

Isoflurane is known to have potential interactions with certain drugs, including some that are highly protein-bound like the anticoagulant warfarin. The anesthesia team is required to review all current medications, including blood thinners, to manage any potential effects safely during the procedure.


Q: Are patients with heart problems allowed to use Isoflurane?

Isoflurane causes a dose-dependent decrease in blood pressure. Special care is required for patients with pre-existing heart conditions, particularly those with Coronary Artery Disease. The anesthetic team is responsible for carefully selecting and monitoring the dosage to maintain patient safety.


Q: Do routine medications for high blood pressure interact with Isoflurane?

Yes, regulatory documents indicate that some medications for high blood pressure, such as calcium channel blockers and beta-blockers, may interact. When used together, these combinations could potentially enhance the effect of Isoflurane on the cardiovascular system, leading to increased hypotension (low blood pressure).


Q: What makes Isoflurane a volatile anesthetic agent?

Isoflurane is classified as a volatile anesthetic because it is a liquid at room temperature but must be precisely vaporized for administration. Its chemical properties allow it to change into a vapor for delivery via the inhalation route.


Q: Is there research looking at newer applications or delivery methods for Isoflurane?

Yes. While Isoflurane's primary use is surgical anesthesia, research has investigated its use for extended deep sedation in controlled settings like the Intensive Care Unit ( ICU). Studies continually refine its role in various critical care contexts.


Q: What happens to the waste gas from Isoflurane in the operating room?

In clinical settings, specialized scavenging systems are mandated by regulatory guidelines. These systems are designed to actively capture and remove any Waste Anesthetic Gases (WAG) from the environment.


Q: Is Isoflurane generally more common for animal or human surgery?

Isoflurane is a key agent in human surgical anesthesia worldwide. It is also frequently utilized in veterinary medicine for anesthetizing animals, demonstrating its established and widespread application across medical fields.


Q: Does Isoflurane cause a sore throat after the breathing tube is removed?

While regulatory reports list adverse reactions like coughing that relate to the airway, any discomfort in the throat is typically associated with the mechanical devices used to manage the airway (such as a breathing tube) during the procedure.


Q: Is there a risk of being aware during surgery with Isoflurane?

Intraoperative awareness, where a patient recalls events during surgery, is a known but rare risk associated with general anesthesia. Anesthesia providers utilize established monitoring methods to maintain the appropriate depth of unconsciousness and minimize this risk.


Q: Is there a maximum amount of time a person can safely be under Isoflurane?

Isoflurane is principally used for the duration of a surgical procedure. Clinical studies have explored its prolonged use for sedation over many hours, indicating it can be administered beyond standard surgical duration when managed in a controlled clinical environment under expert supervision.

How should Isoflurane be stored and disposed of?

How to Store and Dispose of Isoflurane?

Isoflurane, a volatile liquid anesthetic, must be stored under specific conditions to maintain its documented stability (typically up to 5 years). It must be stored in a cool, well-ventilated area at controlled room temperature (e.g., 15 C to 30 C) and kept tightly closed to prevent the escape of vapor. Although chemically stable, the container should be kept away from sources of ignition or direct sunlight.

All official labeling mandates that the container be kept out of the sight and reach of children.

Disposal

Disposal of unused product or waste material must follow local hazardous chemical waste regulations. Isoflurane must not be poured down the drain or disposed of in common household trash due to its classification as a hazardous chemical.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Isoflurane found in:

A-Z Index: